Novartis Ag (NVS) Other Non-Current Liabilities (2009 - 2026)

Novartis Ag has disclosed Other Non-Current Liabilities across 18 years of filings, most recently posting $3.9 billion for Q2 2026.

• In Q2 2026, Other Non-Current Liabilities fell 8.18% year-over-year to $3.9 billion; the TTM figure through Jun 2026 stood at $3.9 billion (down 8.18% YoY), while the FY2025 annual figure was $4.1 billion, up 1.42% from the prior year.
• Other Non-Current Liabilities came in at $3.9 billion for Q2 2026 at Novartis Ag, down from $4.0 billion in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $6.0 billion in Q1 2022 to a low of $415.0 million in Q1 2023.
• Average Other Non-Current Liabilities over 5 years is $4.3 billion, with a median of $4.3 billion recorded in 2024.
• Year-over-year, Other Non-Current Liabilities tumbled 93.03% in 2023 and jumped 926.27% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $4.9 billion in 2022, then fell by 7.81% to $4.5 billion in 2023, then slipped by 9.9% to $4.1 billion in 2024, then gained by 1.42% to $4.1 billion in 2025, then fell by 5.76% to $3.9 billion in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $3.9 billion in Q2 2026, $4.0 billion in Q1 2026, and $4.1 billion in Q4 2025.